Supaveda · Ingredient Spotlight
Shallaki
Boswellia serrata Roxb. — Indian Frankincense
Also known as: Salai Guggul · Salai · Kundur · Dhup · Olibanum · Luban · Boswellia · Sallaki · Mandagandha
Shallaki (Boswellia serrata) addresses the inflammatory pathway that NSAIDs — ibuprofen, diclofenac, naproxen — cannot touch. While pharmaceutical anti-inflammatories block the COX enzyme pathway, the 5-lipoxygenase (5-LOX) leukotriene pathway continues unchecked, perpetuating the inflammation that drives chronic joint disease, bowel inflammation, and airway hyperreactivity. AKBA — Boswellia's primary active compound — is the most selective natural 5-LOX inhibitor discovered, and it targets precisely this gap.
A medium-to-large deciduous tree of the Burseraceae family, native to the dry hill forests of peninsular India, B. serrata produces a gum-resin from incisions in its bark — the Indian equivalent of the frankincense of the ancient Mediterranean trade routes. In Ayurveda, this resin (Shallaki or Salai guggul) has been the primary treatment for Sandhivata (joint disease, including osteoarthritis and rheumatoid arthritis) for over two millennia. 1 Modern pharmacology has confirmed why, with extraordinary precision: a 2024 double-blind, randomised, multi-centre, placebo-controlled trial published in Frontiers in Pharmacology showed improvements in knee osteoarthritis within five days of starting Boswellia extract supplementation — the fastest-acting natural anti-inflammatory validated in a modern RCT for joint disease. 2 A meta-analysis of seven RCTs in 545 patients confirmed Boswellia extract is significantly more effective than placebo, ibuprofen, or glucosamine for reducing OA pain, stiffness, and functional impairment. 3
🌳 The Frankincense Story — India's Sacred Resin & the Pathway NSAIDs Miss
The genus Boswellia gave the ancient world its most prized aromatic substance: frankincense. The East African and Arabian species (B. sacra, B. carterii) produced the incense burned in the temples of ancient Egypt, Rome, and Jerusalem — traded more valuably than gold along the Incense Route for three thousand years. Boswellia serrata — the Indian species — produced the equivalent in Ayurvedic civilisation: Shallaki, the resin that Ayurvedic physicians prescribed not for fragrance but as one of their most powerful anti-inflammatory medicines. The sacred and the therapeutic were always one in traditional medicine. 1
The pharmacological discovery that elevated Shallaki from traditional herb to pharmacological landmark came in 1992, when Safayhi et al. published a study in the Journal of Pharmacology and Experimental Therapeutics identifying boswellic acids — and particularly AKBA (3-O-acetyl-11-keto-β-boswellic acid) — as novel, specific, non-redox inhibitors of 5-lipoxygenase (5-LOX). 4 This was a landmark discovery for two reasons. First, 5-LOX is the enzyme that converts arachidonic acid into leukotrienes — the inflammatory mediators that drive asthma, chronic bowel inflammation, and the leukotriene-mediated component of joint inflammation that COX inhibitors (NSAIDs) cannot address. Second, AKBA's mechanism was structurally distinct from existing 5-LOX inhibitors, and its selectivity was remarkable: AKBA does not inhibit COX, does not act through redox mechanisms (avoiding the non-specific oxidative side effects of early 5-LOX inhibitors), and does not inhibit 12-LOX — it targets 5-LOX and its accessory protein FLAP with precision. This means Boswellia provides true pharmacological complementarity to NSAIDs: together they inhibit both the COX and 5-LOX inflammatory pathways — a combination that has shown additive therapeutic effects in OA research.
At a Glance — Key Evidence-Backed Benefits
Traditional Ayurvedic Uses
Shallaki is documented in the Sushruta Samhita, the Charaka Samhita, and the Ashtanga Hridayam as the primary herb for Sandhivata (joint disease — the classical correlate of osteoarthritis and rheumatoid arthritis), Vatasonita (gout), and inflammatory conditions of the musculoskeletal system. Its Sanskrit name Shallaki derives from its characteristic aromatic resin — the plant that bears the sacred aromatic gum. Salai guggul — "the Salai resin" — is the classical pharmaceutical name for the prepared gum resin; Kundur is its Unani designation, where it appears as the primary anti-inflammatory herb for articular disease. 1
The classical Ayurvedic description of Shallaki as Kaphavatahara — reducing both Kapha and Vata doshas — directly maps to its dual pharmacological activity: reducing inflammatory Kapha (the moist, heavy, phlegm-producing imbalance underlying mucosal inflammation, bowel disease, and joint swelling) and the dry, degenerative, pain-driven Vata component of joint disease (stiffness, cracking, atrophy, pain). Classical physicians prescribed Shallaki in Ghrita (medicated ghee) preparations for long-term joint Rasayana use, and topically as a poultice for localised joint swelling — a dual internal-and-external approach that mirrors modern Boswellia's use in oral supplements and topical preparations. 5
Ayurvedic Properties (Guna)
The sweet (Madhura) rasa alongside bitter (Tikta) is pharmacologically significant — unlike purely bitter anti-inflammatory herbs, Shallaki has a tissue-nourishing quality that supports its use in Rasayana (long-term rejuvenative) applications for joints. The heating potency drives resin compounds deep into joint tissues and synovial spaces, the classical explanation for the topical warming application to arthritic joints.
Conditions Traditionally Treated
- Joint disease (Sandhivata) — the primary classical indication; osteoarthritis, rheumatoid arthritis, gout; swelling, stiffness, and pain
- Inflammatory bowel conditions — Grahani (chronic colitis, IBS); classical astringent and anti-inflammatory for intestinal inflammation
- Respiratory conditions — asthma (Shwasa); bronchitis; the leukotriene-reducing action specifically relevant to leukotriene-mediated asthma
- Wounds and ulcers (Vrana) — topical application of resin directly to wounds; antimicrobial and healing properties
- Fever (Jwara) — antipyretic action; reduces inflammatory fever
- Skin disease (Kushtha) — topical resin for psoriasis, eczema, and skin infections; confirmed in a 2023 clinical study
- Liver and hepatic conditions — hepatoprotective properties; bile duct support; liver cleansing
- Neurological and brain conditions — traditionally used for enhancing memory and cognition; preliminary research on neuroprotection
- Gynaecological conditions — menstrual pain regulation; uterine anti-inflammatory effects
- Oral health — gum resin used for mouth and throat conditions, sore throat, and gum disease; the incense application connected to antimicrobial properties
Key Active Compounds
The pharmacological activity of Boswellia serrata is concentrated in its pentacyclic triterpene acid fraction — the boswellic acids (BAs) — extracted from the gum resin. Unlike most plant medicines where dozens of compounds contribute roughly equally, Boswellia's activity hierarchy is relatively clear: AKBA is the most potent, followed by KBA, with β-BA and ABA contributing secondary activity. The ratio of boswellic acids in standardised extracts determines therapeutic potency. 4
Primary Bioactive Constituents
How Shallaki Works — Four Pharmacological Mechanisms
Boswellia's therapeutic breadth across osteoarthritis, inflammatory bowel disease, and asthma is explained by four distinct but interconnected mechanisms — all centred on AKBA's precise targeting of the leukotriene-NF-κB inflammatory axis that NSAIDs bypass entirely. 4
Shallaki's Four Core Therapeutic Mechanisms
What the Research Says
The most recent major RCT is a double-blind, randomised, three-arm, parallel-group, multi-centre, placebo-controlled trial published in Frontiers in Pharmacology in July 2024 (doi: 10.3389/fphar.2024.1428440), conducted at two hospital sites in India (Nuha Hospital, Guntur, and Mysore Medical College) between January and November 2023, registered with the Clinical Trial Registry of India (CTRI/2022/11/047,397). 2 One hundred and five individuals with knee osteoarthritis were randomised to 90 days of standardised Boswellia serrata extract at two doses or placebo. The primary finding — and the one most clinically remarkable — was that significant improvements in knee OA outcomes were measurable within five days of starting treatment. This is important because it establishes that Boswellia's mechanism (5-LOX leukotriene pathway inhibition and NF-κB suppression) produces clinical effects with a speed comparable to pharmaceutical anti-inflammatories, challenging the assumption that natural plant medicines require weeks to show measurable effects. At 90 days, all primary and secondary outcomes (pain, stiffness, physical function) showed significant improvement over placebo across both dose groups, with the higher-dose group showing superior outcomes.
The landmark 5-Loxin trial by Sengupta et al. (2008, Arthritis Research & Therapy, PMC2575633) enrolled 75 knee OA patients in a 90-day double-blind, randomised, placebo-controlled study. Patients received either 100 mg/day or 250 mg/day of 5-Loxin (standardised to 30% AKBA) or placebo. 6 The findings were significant on multiple dimensions. First, clinically significant improvements in pain and physical function were recorded in the 250 mg group as early as day 7 of treatment — establishing a rapid onset that challenged prevailing assumptions about herbal anti-inflammatory timelines. By day 90, both doses showed statistically and clinically significant improvements in all measured outcomes: visual analogue scale (VAS) pain, Lequesne's Functional Index, and WOMAC (Western Ontario and McMaster Universities OA Index). Second, and arguably more clinically significant, was the effect on synovial fluid MMP-3. Matrix metalloproteinase-3 is the cartilage-degrading enzyme at the centre of OA disease progression — its reduction is the most direct evidence available for disease modification rather than merely symptomatic relief. At day 90, the placebo group showed no significant MMP-3 change. The 100 mg 5-Loxin group showed a 31.37% reduction (p=0.002). The 250 mg 5-Loxin group showed a 46.4% reduction (p<0.001). This MMP-3 reduction is pharmacologically significant: it suggests Boswellia may not only reduce pain but may slow the cartilage degradation that drives OA progression — a property that no NSAID possesses.
The systematic review and meta-analysis by Yu et al. (2020, BMC Complementary Medicine and Therapies, PMC7368679) pooled data from seven randomised controlled trials involving 545 patients with OA across multiple preparations and dosing regimens of Boswellia extract. 3 The primary outcomes were VAS pain score, WOMAC pain, WOMAC stiffness, WOMAC function, and Lequesne Index. The pooled analysis confirmed: VAS pain reduction WMD −8.33 (95% CI: −11.19, −5.46; p<0.00001); WOMAC pain reduction WMD −14.22 (95% CI: −22.34, −6.09; p=0.0006); WOMAC stiffness WMD −10.04 (95% CI: −15.86, −4.22; p=0.001). Critically, the meta-analysis confirmed Boswellia extract was significantly more effective than not only placebo, but also ibuprofen and glucosamine sulfate as active comparators — positioning it not merely as a placebo-superior supplement but as a clinically competitive anti-inflammatory agent. A recommended treatment duration of at least 4 weeks was suggested based on the temporal pattern of effect across trials. The MDPI 2023 clinical trial (Murcia, Spain) using a Boswellia + omega-3 combination further confirmed significant pain reduction vs placebo in healthy adults over 40 with persistent knee pain. 7
The 5-LOX/leukotriene pathway is the primary driver of intestinal inflammation in ulcerative colitis — leukotrienes B4, C4, D4, and E4 are elevated in the colonic mucosa of UC patients and are directly implicated in epithelial barrier dysfunction, neutrophil recruitment, and inflammatory cytokine production in the bowel. AKBA's selective 5-LOX inhibition therefore has a mechanistic rationale specifically for IBD that is distinct from its joint applications. 8
A clinical trial by Gupta et al. (1997, European Journal of Medical Research) enrolled UC patients and randomised them to Boswellia serrata extract (350 mg three times daily) or sulfasalazine (1 g three times daily) for six weeks. The Boswellia group achieved clinical remission in 82% of patients, compared to 75% in the sulfasalazine group — with remission defined by stool properties, rectal histopathology, haemoglobin, serum iron, calcium, phosphorus, protein, and total leukocyte counts. While this is a single small trial requiring replication in larger RCTs, the mechanistic rationale is strong: sulfasalazine's mechanism includes 5-aminosalicylate, which itself acts partly through 5-LOX inhibition. The superior numerics for Boswellia (82% vs 75%) are consistent with a more selective and potent 5-LOX inhibition by AKBA. A Crohn's disease trial found Boswellia non-inferior to mesalazine (the gold-standard first-line therapy) by standard disease severity scoring. The intestinal epithelial barrier study (PMC4425476) confirmed that BSE and AKBA directly protect tight junction integrity in intestinal cell monolayers exposed to oxidative and inflammatory damage — providing a cellular mechanism for the clinical IBD findings.
The 5-LOX pathway is also the primary pharmacological target in leukotriene-mediated asthma — the same molecular mechanism exploited by montelukast (Singulair), one of the most widely prescribed pharmaceutical asthma drugs. A double-blind, placebo-controlled, 6-week clinical study by Gupta et al. (1998, European Journal of Medical Research) evaluated Boswellia serrata gum resin in patients with bronchial asthma. 9 The trial found that 70% of patients in the Boswellia group showed significant improvement in asthma parameters, compared to only 27% in the placebo group. Improvement was measured across multiple outcomes: reduction in number of asthma attacks, reduction in severity of dyspnoea, improvement in peak expiratory flow rate, reduction in eosinophilia, and reduction in erythrocyte sedimentation rate. The mechanistic parallel with pharmaceutical leukotriene receptor antagonists is direct: both target the leukotriene pathway. Boswellia operates upstream by inhibiting the enzyme (5-LOX) that produces leukotrienes, while montelukast operates downstream by blocking the receptor that leukotrienes bind. The 5-LOX boswellic acid review (PMC10858840) also confirmed preclinical evidence of Boswellia's efficacy in allergic asthma models through leukotriene and IL-4/IL-13 pathway modulation. 5
The molecular mechanism of AKBA's NF-κB inhibition was precisely characterised by Takada et al. (2006, Journal of Biological Chemistry, PMID: 16493072). The study demonstrated that AKBA potentiates apoptosis induced by TNF-α and chemotherapeutic agents, suppresses TNF-induced invasion, and inhibits osteoclastogenesis — all through NF-κB suppression. 10 The mechanistic detail was unusually precise: AKBA does not directly inhibit NF-κB's DNA binding, but suppresses the upstream activation cascade — specifically inhibiting IκBα kinase (IKK), which prevents IκBα phosphorylation, ubiquitination, and degradation, thereby blocking p65 nuclear translocation. This IKK inhibition was traced further upstream to Akt kinase suppression. The study found AKBA suppresses constitutive as well as inducible NF-κB activation in tumour cells, with downstream downregulation of NF-κB-regulated antiapoptotic gene products (Bcl-2, survivin), proliferative gene products (cyclin D1), and angiogenic gene products (VEGF). This molecular precision — tracing AKBA's effect from Akt → IKK → IκBα → NF-κB → downstream inflammatory genes — places AKBA among the most pharmacologically well-characterised natural anti-inflammatory compounds, with a level of mechanistic detail comparable to many pharmaceutical NF-κB inhibitors in development. The same study confirmed AKBA's inhibition of osteoclastogenesis — directly relevant to bone erosion in inflammatory arthritis — and invasion suppression relevant to cancer biology.
Clinical Evidence at a Glance
Traditional Use & Modern Dosage
The bioavailability of boswellic acids — particularly AKBA — is significantly enhanced when taken with fat. This is the pharmacological basis of Aflapin (AKBA combined with nonvolatile boswellia oil), and of the classical Ayurvedic preparation of Shallaki in Ghrita (medicated ghee) — fat-based preparations that Ayurvedic physicians arrived at through clinical observation long before lipid solubility was understood. All modern clinical evidence uses standardised extracts; crude resin is effective but provides variable AKBA content.
| Form | Traditional Preparation | Typical Dose / Use |
|---|---|---|
| Gum Resin (Shallaki Niryasa) | Raw gum resin dissolved in warm water or ghee; the original classical preparation; highly variable boswellic acid content between batches | 1–3 g raw resin daily with warm water and ghee; classical Sandhivata preparation; inconsistent AKBA content makes standardised extracts preferred for therapeutic use |
| Medicated Ghee (Shallaki Ghrita) | Gum resin processed into clarified butter with milk and other herbs; classical long-term Rasayana for joint regeneration | 5–10 g daily with warm milk; long-term joint Rasayana; the ghee base dramatically enhances boswellic acid absorption — the classical pharmacokinetic optimisation |
| Standardised Extract (65% BAs) | Boswellic acid-standardised extract (typically 65% total boswellic acids including various AKBA percentages); the most widely used modern form | 300–400 mg three times daily (900–1,200 mg/day); take with a fat-containing meal; the form used in multiple positive RCTs including the original Kimmatkar et al. and Gupta et al. trials; minimum 4 weeks for full effect |
| 5-Loxin (30% AKBA-enriched) | Standardised extract enriched to 30% AKBA through selective enrichment; the form used in the landmark Sengupta et al. RCT (250 mg = 75 mg AKBA) | 100–250 mg/day; 7-day onset at 250 mg confirmed; 90-day full response; lower dose required vs standard extract due to AKBA enrichment; take with food |
| Aflapin (20% AKBA + boswellia oil) | AKBA enriched with boswellia nonvolatile oil fraction; the oil enhances AKBA bioavailability — a modern pharmacokinetic improvement on classical ghee-based preparations | 100 mg/day (lower effective dose due to superior AKBA bioavailability from oil component); confirmed effective in head-to-head trials vs 5-Loxin; good option for oil-enhanced bioavailability without additional fat needed at mealtime |
| Topical Application | Resin paste or oil applied directly to arthritic joints; traditional poultice for localised joint swelling; modern topical gels available | Applied 2–3× daily to affected joints; classical topical anti-inflammatory; warming effect assists joint mobility; can be used alongside oral supplementation for combined systemic and local effect |
Supaveda Products with Shallaki
Shallaki is the 5-LOX-targeting dimension in Supaveda's joint and inflammation formulas — providing the pharmacological coverage that turmeric's COX inhibition cannot reach:
Shallaki is the pharmacological cornerstone of SupaJoint's dual anti-inflammatory approach: while Haridra (turmeric) blocks the COX-2 pathway and NF-κB through curcumin, Shallaki blocks the 5-LOX leukotriene pathway through AKBA — the pathway that NSAIDs miss entirely and that drives the leukotriene-mediated component of joint swelling, synovial inflammation, and cartilage degradation. Together they provide the most complete natural coverage of the two primary inflammatory enzyme pathways, with evidence of MMP-3 reduction (cartilage protection) and pain reduction that in clinical trials has been confirmed superior to ibuprofen alone. Ashwagandha provides the third dimension: cortisol-mediated systemic inflammation that drives both the initial injury response and the chronic progression of joint disease. Three herbs, three distinct mechanisms, one clinical target.
In classical Chyawanprash formulations designed for longevity and systemic health, Shallaki provides the anti-inflammatory resin dimension — its boswellic acids working through the 5-LOX pathway to reduce the low-grade systemic leukotriene-driven inflammation that accumulates with age and accelerates tissue degeneration. In Supa Life, Shallaki complements Haridra's NF-κB inhibition and Amla's DNA-protective antioxidant action — creating three-pathway anti-inflammatory coverage in a daily food-grade Rasayana format. The ghee-equivalent base of the preserve form enhances boswellic acid absorption — the pharmacokinetic rationale that Ayurvedic physicians understood through clinical observation.
Safety & Precautions
Boswellia serrata has one of the most rigorously tested safety profiles of any Ayurvedic herb — acute and subchronic toxicity studies confirm no toxic manifestations at doses 2,000–3,000 times the human equivalent dose, and the genotoxicity (AMES) assay found no mutagenic activity. Multiple human clinical trials have confirmed it is well-tolerated at therapeutic doses, with side effects limited to mild, self-resolving gastrointestinal complaints in a small proportion of participants. It does not cause the GI ulceration, renal dysfunction, or cardiovascular risk associated with long-term NSAID use. 6
Please Note
- Pregnancy: Boswellia has traditional uses as an emmenagogue (stimulating menstrual flow) and some traditional descriptions of uterine-stimulating effects. Therapeutic doses during pregnancy are not established as safe; food-level aromatic use is not associated with risk, but supplementation should be avoided without professional guidance.
- Anticoagulants: Some preliminary evidence suggests boswellic acids may have mild antiplatelet effects. Those on warfarin, aspirin, clopidogrel, or other anticoagulants should inform their prescribing physician and monitor for additive antiplatelet effects.
- Drug interactions — boswellic acids and drug metabolism: Boswellic acids may inhibit certain cytochrome P450 enzymes (CYP1A2, CYP3A4). Those on multiple medications metabolised by these pathways should seek pharmacy advice before adding Boswellia supplementation to their regimen.
- Gastrointestinal sensitivity: The most common side effects reported in clinical trials are mild GI symptoms — nausea, diarrhoea, or gastric discomfort — in a small minority of participants. Taking Boswellia with food (preferably a fat-containing meal) reduces the likelihood of GI side effects and enhances AKBA absorption simultaneously.
- Cancer patients: While AKBA has demonstrated anticancer properties in preclinical research, those with cancer should not use Boswellia except on the explicit advice of their oncologist. Interactions with chemotherapy through P450 enzyme pathways are a concern, and self-treating cancer with herbal supplements is not appropriate.
- Liver and kidney disease: Safety has not been formally established in severe hepatic or renal impairment. Those with significant liver or kidney disease should consult their healthcare provider before supplementation.
Key Takeaways
Evidence-backed bullet points:
AKBA targets the inflammatory pathway NSAIDs miss — ibuprofen, diclofenac, and naproxen block COX enzymes; AKBA selectively inhibits 5-lipoxygenase (5-LOX), the enzyme that produces leukotrienes. Together they cover both primary inflammatory enzyme pathways — Boswellia provides the complementary mechanism that pharmaceutical anti-inflammatories leave open
Significant improvements in knee OA within 5 days — confirmed in a 2024 double-blind, randomised, multi-centre, placebo-controlled trial (Frontiers in Pharmacology, n=105). Earlier 5-Loxin RCT confirmed significant improvement at 7 days with 250 mg — speed of onset comparable to pharmaceutical anti-inflammatories
46.4% reduction in synovial MMP-3 (p<0.001) at 90 days with 250 mg 5-Loxin vs 0% change in placebo — MMP-3 is the cartilage-degrading enzyme that drives OA progression; its significant reduction suggests Boswellia may protect cartilage, not merely mask pain
Meta-analysis of 7 RCTs in 545 OA patients: Boswellia extract significantly more effective than placebo, ibuprofen, AND glucosamine sulfate for VAS pain (p<0.00001), WOMAC pain (p=0.0006), and WOMAC stiffness (p=0.001)
The sacred frankincense of antiquity — Indian Shallaki is the same genus as the Boswellia traded more valuably than gold along the ancient Incense Route and burned in the temples of Egypt, Rome, and Jerusalem for three millennia. The sacred and the therapeutic were always one
82% UC remission with Boswellia (350 mg tds, 6 weeks) vs 75% with sulfasalazine in a clinical trial — the 5-LOX leukotriene pathway is a primary driver of colonic inflammation in UC, making Boswellia pharmacologically rational for IBD where NSAIDs (COX inhibitors) would worsen symptoms
70% asthma improvement vs 27% placebo in a double-blind trial — the same 5-LOX pathway targeted by montelukast (Singulair), one of the most prescribed pharmaceutical asthma drugs. Boswellia inhibits 5-LOX upstream (enzyme blockade); montelukast blocks downstream (receptor blockade)
AKBA directly suppresses NF-κB via IκBα kinase (IKK) inhibition — the master transcription factor controlling 200+ inflammatory genes, traced in precise molecular detail through the Akt→IKK→IκBα→p65 cascade by Takada et al. (2006, Journal of Biological Chemistry)
No GI or cardiovascular risks — safety testing confirmed no toxicity at doses 2,000–3,000× the human equivalent; no GI ulceration (unlike NSAIDs); AMES test negative for genotoxicity. The safest route to 5-LOX inhibition with no pharmaceutical drug currently matching its precision and safety profile
Take with fat for maximum AKBA absorption — boswellic acids are fat-soluble; a fat-containing meal increases bioavailability significantly. Ayurvedic physicians arrived at this conclusion through clinical observation (prescribing Shallaki in Ghrita — medicated ghee) long before lipid pharmacokinetics was understood
References
- Roy, N.K., Parama, D., Banik, K., Bordoloi, D., Devi, A.K., Thakur, K.K. et al. (2019) 'An update on pharmacological potential of boswellic acids against chronic diseases', International Journal of Molecular Sciences, 20(17), p.4101. doi: 10.3390/ijms20174101. Also: ScienceDirect Topics — Boswellia serrata overview. [Shallaki classical Sanskrit name, Salai guggul pharmaceutical name, Kundur Unani designation; Sushruta Samhita and Charaka Samhita documentation; Sandhivata primary indication; frankincense trade route history; Kaphavatahara classical property; Burseraceae family; gum resin source; Indian frankincense vs Arabian frankincense distinction; all traditional conditions treated].
- Majeed, A., Majeed, S., Satish, G., Manjunatha, R., Rabbani, S.N., Patil, N.V.P. and Mundkur, L. (2024) 'A standardized Boswellia serrata extract shows improvements in knee osteoarthritis within five days — a double-blind, randomized, three-arm, parallel-group, multi-center, placebo-controlled trial', Frontiers in Pharmacology, 15, p.1428440. doi: 10.3389/fphar.2024.1428440. [2024 primary DB-RCT; n=105; two sites; 90 days; CTRI/2022/11/047,397; significant improvements within 5 days of treatment; both dose groups significant vs placebo at 90 days; all primary and secondary outcomes; GCP compliance confirmed].
- Yu, G., Xiang, W., Zhang, T., Zeng, L., Yang, K. and Li, J. (2020) 'Effectiveness of Boswellia and Boswellia extract for osteoarthritis patients: a systematic review and meta-analysis', BMC Complementary Medicine and Therapies, 20(1), p.225. PMC7368679. doi: 10.1186/s12906-020-02985-6. [7 RCTs; 545 patients; VAS WMD −8.33 (95% CI −11.19, −5.46; p<0.00001); WOMAC pain WMD −14.22 (95% CI −22.34, −6.09; p=0.0006); WOMAC stiffness WMD −10.04 (p=0.001); superior to placebo, ibuprofen, and glucosamine sulfate; recommended minimum 4-week treatment duration; safety confirmed across all trials].
- Safayhi, H., Mack, T., Sabieraj, J., Anazodo, M.I., Subramanian, L.R. and Ammon, H.P. (1992) 'Boswellic acids: novel, specific, nonredox inhibitors of 5-lipoxygenase', Journal of Pharmacology and Experimental Therapeutics, 261(3), pp.1143–1146. PMID: 1602379. Also: Sailer, E.R., Subramanian, L.R., Rall, B., Hoernlein, R.F., Ammon, H.P. and Safayhi, H. (1996) 'Acetyl-11-keto-β-boswellic acid (AKBA): structure requirements for binding and 5-lipoxygenase inhibitory activity', British Journal of Pharmacology, 117(3), pp.615–618. PMC1909327. [Landmark 1992 characterisation of boswellic acids as novel, specific, non-redox 5-LOX inhibitors; AKBA most potent and selective; no COX inhibition; no 12-LOX inhibition; distinct from redox-based 5-LOX inhibitors; FLAP accessory protein inhibition; primary mechanism characterisation paper].
- PMC10858840 — 'The journey of boswellic acids from synthesis to pharmacological activities', Naunyn-Schmiedeberg's Archives of Pharmacology, 2024. [Comprehensive boswellic acid review; asthma — Liu et al. 2015; allergic asthma leukotriene pathway; OA, RA, gastric colitis, autoimmune encephalomyelitis; Boswellia COVID-19 RCT (Inflawell® 40% BA, 14 days, significant oxygen saturation increase, reduced hospitalization duration); hypolipidemic properties; hepatoprotective RCT in T2DM — significant liver enzyme reduction; memory and cognition enhancement — Farshchi et al. 2010; skin whitening and anti-wrinkle].
- Sengupta, K., Alluri, K.V., Satish, A.R., Mishra, S., Golakoti, T., Sarma, K.V. et al. (2008) 'A double blind, randomized, placebo controlled study of the efficacy and safety of 5-Loxin for treatment of osteoarthritis of the knee', Arthritis Research & Therapy, 10(4), p.R85. PMC2575633. doi: 10.1186/ar2461. PMID: 18667054. [Primary 5-Loxin RCT; n=75; 90 days; 100 mg and 250 mg groups; significant pain and function improvement 7 days at 250 mg; VAS, Lequesne, WOMAC all significant; MMP-3 synovial fluid: 31.37% reduction at 100 mg (p=0.002), 46.4% reduction at 250 mg (p<0.001) vs 0% placebo change; safety: all haematological, biochemical and urine parameters unchanged vs placebo; toxicity at 2,000–3,000× HED confirmed no toxic manifestations; AMES assay genotoxicity negative].
- Pallarés-Martínez, V., Martínez-Rodríguez, A., García-Muñoz, A.M. et al. (2023) 'Efficacy of Boswellia serrata extract and/or an omega-3-based product for improving pain and function in people older than 40 years with persistent knee pain: a randomized double-blind controlled clinical trial', Nutrients, 15(17), p.3848. doi: 10.3390/nu15173848. MDPI. [UCAM, Murcia, Spain; January–November 2022; Boswellia + omega-3 combination vs placebo; significant pain reduction; QoL, functional mobility, muscle strength, sleep quality secondary outcomes; prior meta-analysis cited — Boswellia or its extracts more effective than placebo, ibuprofen, or glucosamine sulfate in 7-RCT meta-analysis].
- Gupta, I., Parihar, A., Malhotra, P., Singh, G.B., Lüdtke, R., Safayhi, H. and Ammon, H.P. (1997) 'Effects of Boswellia serrata gum resin in patients with ulcerative colitis', European Journal of Medical Research, 2(1), pp.37–43. PMID: 9049593. Also: PMC4425476 — Boswellia serrata preserves intestinal epithelial barrier from oxidative and inflammatory damage; TEER and permeability protection in Caco-2 monolayers; ROS quenching; tight junction preservation; 5-LOX pathway as primary UC mechanism; leukotriene B4 elevation in UC colonic mucosa; sulfasalazine comparison 82% vs 75% remission; histopathology, haemoglobin, serum iron, protein, leukocyte counts all improved. Also: Gupta et al. 2001 chronic colitis — 14/20 Boswellia vs 4/10 sulfasalazine remission.
- Gupta, I., Gupta, V., Parihar, A., Gupta, S., Lüdtke, R., Safayhi, H. and Ammon, H.P. (1998) 'Effects of Boswellia serrata gum resin in patients with bronchial asthma: results of a double-blind, placebo-controlled, 6-week clinical study', European Journal of Medical Research, 3(11), pp.511–514. PMID: 9810030. [Asthma DB-PC trial; 70% Boswellia vs 27% placebo showing significant improvement; asthma attack frequency, dyspnoea severity, PEFR, eosinophilia, ESR all improved; 5-LOX mechanism as parallel to montelukast (leukotriene receptor antagonist) explained; upstream (enzyme) vs downstream (receptor) inhibition distinction].
- Takada, Y., Ichikawa, H., Badmaev, V. and Aggarwal, B.B. (2006) 'Acetyl-11-keto-beta-boswellic acid potentiates apoptosis, inhibits invasion, and abolishes osteoclastogenesis by suppressing NF-κB and NF-κB-regulated gene expression', Journal of Biological Chemistry, 281(26), pp.17103–17111. doi: 10.1074/jbc.M601813200. PMID: 16493072. [Precise NF-κB mechanism: Akt → IKK → IκBα phosphorylation/ubiquitination → p65 nuclear translocation; AKBA does not directly inhibit NF-κB DNA binding but blocks upstream IKK activation via Akt suppression; downregulation of antiapoptotic (Bcl-2, survivin), proliferative (cyclin D1), angiogenic (VEGF) NF-κB-regulated gene products; osteoclastogenesis inhibition; invasion suppression; apoptosis potentiation with TNF and chemotherapeutic agents; constitutive and inducible NF-κB suppressed in tumour cells].